1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Metastatic Ovarian Cancer-Pipeline Insights, 2017


DelveInsight’s, “ Metastatic Ovarian Cancer-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Metastatic Ovarian Cancer. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Metastatic Ovarian Cancer. DelveInsight’s Report also assesses the Metastatic Ovarian Cancer therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

- The report provides competitivepipeline landscape of Metastatic Ovarian Cancer
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Metastatic Ovarian Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Metastatic Ovarian Cancer and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Metastatic Ovarian Cancer-Pipeline Insights, 2017
Illustrative

- Metastatic Ovarian Cancer Overview
- Metastatic Ovarian Cancer Pipeline Therapeutics
- Metastatic Ovarian Cancer Therapeutics under Development by Companies
- Metastatic Ovarian Cancer Filed and Phase III Products
- Comparative Analysis
- Metastatic Ovarian Cancer Phase II Products
- Comparative Analysis
- Metastatic Ovarian Cancer Phase I and IND Filed Products
- Comparative Analysis
- Metastatic Ovarian Cancer Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Metastatic Ovarian Cancer - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Metastatic Ovarian Cancer - Discontinued Products
- Metastatic Ovarian Cancer - Dormant Products
- Companies Involved in Therapeutics Development for Metastatic Ovarian Cancer
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Metastatic Ovarian Cancer, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Metastatic Ovarian Cancer Assessment by Monotherapy Products
- Metastatic Ovarian Cancer Assessment by Combination Products
- Metastatic Ovarian Cancer Assessment by Route of Administration
- Metastatic Ovarian Cancer Assessment by Stage and Route of Administration
- Metastatic Ovarian Cancer Assessment by Molecule Type
- Metastatic Ovarian Cancer Assessment by Stage and Molecule Type
- Metastatic Ovarian Cancer Therapeutics - Discontinued Products
- Metastatic Ovarian Cancer Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Metastatic Ovarian Cancer, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Metastatic Ovarian Cancer Assessment by Monotherapy Products
- Metastatic Ovarian Cancer Assessment by Combination Products
- Metastatic Ovarian Cancer Assessment by Route of Administration
- Metastatic Ovarian Cancer Assessment by Stage and Route of Administration
- Metastatic Ovarian Cancer Assessment by Molecule Type
- Metastatic Ovarian Cancer Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
EpiCast Report: Ovarian Cancer - Epidemiology Forecast to 2025

EpiCast Report: Ovarian Cancer - Epidemiology Forecast to 2025

  • $ 3995
  • Industry report
  • December 2016
  • by GlobalData

EpiCast Report: Ovarian Cancer - Epidemiology Forecast to 2025 Summary Ovarian cancer (OC; International Classification of Diseases, Revision 10 [ICD-10] code: C56) and cancer of the fallopian tubes and ...

Europe Ovarian Cancer Diagnostics and Therapeutics Market - Segmented by Type of Cancer and Geography (2017 - 2022)

Europe Ovarian Cancer Diagnostics and Therapeutics Market - Segmented by Type of Cancer and Geography (2017 - 2022)

  • $ 3850
  • Industry report
  • February 2017
  • by Mordor Intelligence LLP

The European market for ovarian cancer diagnostics and therapeutics accounted for USD 359 million in 2015 and is expected to grow at a CAGR of 10-16% by 2020. Ovarian cancer is caused by an uncontrollable ...

Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics Market - Segmented by Type of Cancer and Geography (2017 - 2022)

Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics Market - Segmented by Type of Cancer and Geography (2017 - 2022)

  • $ 3850
  • Industry report
  • January 2017
  • by Mordor Intelligence LLP

The Asia-Pacific market for ovarian cancer diagnostics and therapeutics accounted for USD 165 million in 2015 and is expected to grow at a CAGR of 10-16% by 2020. Ovarian cancer is caused by an uncontrollable ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US - Forecast

  • March 2017
    2 pages
  • Cancer  

    Pharmaceutical  

  • United States  

View report >

Cancer Statistics in the US

  • March 2017
    23 pages
  • Cancer  

  • United States  

View report >

Breast Cancer Statistics in the US

  • March 2017
    26 pages
  • Breast Cancer  

    Genetic  

  • United States  

View report >

Cancer Statistics

1 month ago

Related Market Segments :

Ovarian Cancer

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.